Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

203 - Incidence of programmed cell death 1 inhibitor-related diarrhea in patients with advanced cancer: A systematic review and meta-analysis

Date

14 Dec 2018

Session

Poster Display session

Presenters

Jiang-Dong Sui

Citation

Annals of Oncology (2018) 29 (suppl_10): x17-x23. 10.1093/annonc/mdy486

Authors

J. Sui, Y. Wang, Y. Wan, Y. Wu

Author affiliations

  • Radiation Oncology Center, Chongqing Cancer Hospital, Chongqing University Cancer Hospital, 400000 - Chongqing/CN
More

Resources

Abstract 203

Background

Programmed cell death 1 (PD-1) inhibitor-related diarrhea is increased due to the rising administration of PD-1 inhibitor across different tumor types. This adverse event is potentially life-threatening, thus requiring appropriate management. However, its incidence among various tumor types is barely known yet.

Methods

Thirty-three original articles of PD-1 inhibitor monotherapy trials were identified based on a PubMed search completed on October 6, 2017. The incidences of all-grade and grade ≥3 diarrhea were collected.

Results

Thirty-three studies containing 7322 patients were included in the meta-analysis. The overall incidence of diarrhea during PD-1 inhibitor monotherapy was 11.3% (95% CI, 9.7%-12.9%) for all-grade and 0.8% (95% CI, 0.6%-1.1%) for grade ≥3 diarrhea. The incidence was higher in renal cell carcinoma (RCC) for both all-grade (14.4% vs 9.4%) and grade ≥3 diarrhea (1.3% vs 0.7%) compared with non-small-cell lung cancer (NSCLC) but only for all-grade diarrhea (14.4% vs 8.5%) compared with urothelial carcinoma. The incidence in melanoma was higher than in NSCLC (15.7% vs 9.4%) and urothelial carcinoma (15.7% vs 8.5%) for all-grade diarrhea but not for grade ≥3 diarrhea. No significant differences were noted between Nivolumab and Pembrolizumab for allgrade diarrhea (11.7% vs 10.7%) or grade ≥3 diarrhea (0.9% vs 0.8%).

Conclusions

The incidence of PD-1 inhibitor-related diarrhea was higher in RCC and melanoma. There was no significant difference in PD-1 inhibitor-related diarrhea between two types of PD-1 inhibitors. These results contribute to heighten clinicians’ awareness of potential adverse events in diverse tumor types.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Radiation Oncology, Chongqing Cancer Institute & Chongqing Cancer Hospital & Chongqing Cancer Center & Chongqing University Cancer Hospital, Chongqing, CN.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.